Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey

This prospective phase IV study aimed to evaluate the efficacy and safety. Response and remission rates were 70% and 40% (week 6) and 67% and 36%, res...

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)

Four arms were randomly assigned to receive 5-FU (5-fluorouracil)-based CT. No significant difference was observed for the median PFS. Adding irinotec...

Intravenous cyclosporine for severe attacks of ulcerative colitis: a survey of Canadian gastroenterologists

A single randomized trial evaluated the use of cyclosporine treatment for severe attacks of ulcerative colitis. Over 90% of respondents believe that f...

Objective benefit of a 1-day training course in endoscopic hemostasis using the "compactEASIE" endoscopy simulator

The Erlangen Active Simulator for Interventional Endoscopy (EASIE) was introduced in 1997. Objective evidence of the benefits of training with this mo...